155 related articles for article (PubMed ID: 21443472)
1. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer.
Bonanno L; Jirillo A; Favaretto A
Curr Drug Targets; 2011 Jun; 12(6):922-33. PubMed ID: 21443472
[TBL] [Abstract][Full Text] [Related]
2. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
Robinson KW; Sandler AB
Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
[TBL] [Abstract][Full Text] [Related]
3. Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?
Halder S; Basu S; Lall SP; Ganti AK; Batra SK; Seshacharyulu P
Expert Opin Ther Targets; 2023; 27(4-5):305-324. PubMed ID: 37243489
[TBL] [Abstract][Full Text] [Related]
4. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.
Dienstmann R; De Dosso S; Felip E; Tabernero J
Mol Oncol; 2012 Feb; 6(1):15-26. PubMed ID: 22189054
[TBL] [Abstract][Full Text] [Related]
5. The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Albers J; Friese-Hamim M; Clark A; Schadt O; Walter-Bausch G; Stroh C; Johne A; Karachaliou N; Blaukat A
Mol Cancer Ther; 2023 Jul; 22(7):833-843. PubMed ID: 36999986
[TBL] [Abstract][Full Text] [Related]
6. [Recent Advances and Prospect of Advanced Non-small Cell Lung Cancer Targeted
Therapy: Focus on Small Molecular Tyrosine Kinase Inhibitors].
Zhang G; Wang H; Ma Z
Zhongguo Fei Ai Za Zhi; 2017 Apr; 20(4):278-286. PubMed ID: 28442018
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review.
Wang C; Zhang Y; Zhang T; Xu J; Yan S; Liang B; Xing D
Int J Biol Macromol; 2023 Dec; 253(Pt 7):127440. PubMed ID: 37839594
[TBL] [Abstract][Full Text] [Related]
8. New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer.
Zhou Y; Takahashi JI; Sakurai H
Biol Pharm Bull; 2024; 47(5):895-903. PubMed ID: 38692865
[TBL] [Abstract][Full Text] [Related]
9. Role of c-Met in cancer: emphasis on lung cancer.
Salgia R
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S52-8. PubMed ID: 19393836
[TBL] [Abstract][Full Text] [Related]
10. Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.
Bylicki O; Paleiron N; Assié JB; Chouaïd C
Onco Targets Ther; 2020; 13():5691-5706. PubMed ID: 32606781
[TBL] [Abstract][Full Text] [Related]
11. Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight.
Damare R; Engle K; Kumar G
Phytother Res; 2024 May; 38(5):2406-2447. PubMed ID: 38433568
[TBL] [Abstract][Full Text] [Related]
12. Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.
Hussain S; Mursal M; Verma G; Hasan SM; Khan MF
Eur J Pharmacol; 2024 May; 970():176484. PubMed ID: 38467235
[TBL] [Abstract][Full Text] [Related]
13. Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer.
Thomas BJ; Guldenpfennig C; Guan Y; Winkler C; Beecher M; Beedy M; Berendzen AF; Ma L; Daniels MA; Burke DH; Porciani D
Mol Ther Nucleic Acids; 2023 Dec; 34():102046. PubMed ID: 37869258
[TBL] [Abstract][Full Text] [Related]
14. Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications.
Shaban N; Kamashev D; Emelianova A; Buzdin A
Cells; 2023 Dec; 13(1):. PubMed ID: 38201251
[TBL] [Abstract][Full Text] [Related]
15. Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.
Luo M; Fu LW
Am J Cancer Res; 2014; 4(6):608-28. PubMed ID: 25520855
[TBL] [Abstract][Full Text] [Related]
16. Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.
Bolcaen J; Nair S; Driver CHS; Boshomane TMG; Ebenhan T; Vandevoorde C
Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34209513
[TBL] [Abstract][Full Text] [Related]
17. Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing.
Liu C; Leighow SM; McIlroy K; Lu M; Dennis KA; Abello K; Brown DJ; Moore CJ; Shah A; Inam H; Rivera VM; Pritchard JR
Cell Rep Med; 2023 Oct; 4(10):101227. PubMed ID: 37852183
[TBL] [Abstract][Full Text] [Related]
18. Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors.
Gillis NK; Rotroff DM; Mesa TE; Yao J; Chen Z; Carulli MA; Yoder SJ; Walko CM; Teer JK; McLeod HL
Oncotarget; 2017 Dec; 8(70):115114-115127. PubMed ID: 29383146
[TBL] [Abstract][Full Text] [Related]
19. Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2.
Wang BW; Huang CH; Liu LC; Cheng FJ; Wei YL; Lin YM; Wang YF; Wei CT; Chen Y; Chen YJ; Huang WC
Front Pharmacol; 2021; 12():614673. PubMed ID: 34267653
[TBL] [Abstract][Full Text] [Related]
20. OncoPDSS: an evidence-based clinical decision support system for oncology pharmacotherapy at the individual level.
Xu Q; Zhai JC; Huo CQ; Li Y; Dong XJ; Li DF; Huang RD; Shen C; Chang YJ; Zeng XL; Meng FL; Yang F; Zhang WL; Zhang SN; Zhou YM; Zhang Z
BMC Cancer; 2020 Aug; 20(1):740. PubMed ID: 32770988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
